Replies to post #106 on Nkarta Inc (NKTX)

[jondoeuk]

The update is expected to include longer-term follow up from patients who were in response as of the previous April '22 data cut-off; clinical data from at least ten new R/R AML patients treated at 1.5B (x3); clinical data from patients who received one or more additional three-dose cycles; and clinical data from a new cohort of patients who received lymphodepletion with cytarabine and fludarabine.

[NY1972]

This one is puzzling. Four patients with MDS were treated, with no response observed.